“The existing scenario has exposed some structural weaknesses from the EU’s medicines provide chain in addition to a higher dependence on non-EU nations for active pharmaceutical ingredients,” Kyriakides explained. She recommended that supply chain concerns be resolved in an EU pharmaceutical techni